S&P 500   4,635.25 (+1.49%)
DOW   34,878.33 (+1.14%)
QQQ   399.09 (+1.34%)
AAPL   167.92 (+1.58%)
MSFT   334.77 (+1.26%)
FB   327.84 (+1.04%)
GOOGL   2,901.36 (+2.23%)
AMZN   3,545.46 (+1.09%)
TSLA   1,164.34 (+1.71%)
NVDA   330.26 (+1.07%)
BABA   128.84 (+1.03%)
NIO   40.09 (+2.45%)
CGC   10.86 (+1.40%)
AMD   159.46 (+0.69%)
GE   96.50 (+1.59%)
MU   88.87 (+5.80%)
T   22.95 (+0.53%)
F   20.21 (+5.32%)
DIS   147.71 (+1.94%)
ACB   6.51 (+1.40%)
PFE   53.32 (-0.76%)
AMC   34.61 (+1.97%)
BA   200.22 (+1.20%)
S&P 500   4,635.25 (+1.49%)
DOW   34,878.33 (+1.14%)
QQQ   399.09 (+1.34%)
AAPL   167.92 (+1.58%)
MSFT   334.77 (+1.26%)
FB   327.84 (+1.04%)
GOOGL   2,901.36 (+2.23%)
AMZN   3,545.46 (+1.09%)
TSLA   1,164.34 (+1.71%)
NVDA   330.26 (+1.07%)
BABA   128.84 (+1.03%)
NIO   40.09 (+2.45%)
CGC   10.86 (+1.40%)
AMD   159.46 (+0.69%)
GE   96.50 (+1.59%)
MU   88.87 (+5.80%)
T   22.95 (+0.53%)
F   20.21 (+5.32%)
DIS   147.71 (+1.94%)
ACB   6.51 (+1.40%)
PFE   53.32 (-0.76%)
AMC   34.61 (+1.97%)
BA   200.22 (+1.20%)
S&P 500   4,635.25 (+1.49%)
DOW   34,878.33 (+1.14%)
QQQ   399.09 (+1.34%)
AAPL   167.92 (+1.58%)
MSFT   334.77 (+1.26%)
FB   327.84 (+1.04%)
GOOGL   2,901.36 (+2.23%)
AMZN   3,545.46 (+1.09%)
TSLA   1,164.34 (+1.71%)
NVDA   330.26 (+1.07%)
BABA   128.84 (+1.03%)
NIO   40.09 (+2.45%)
CGC   10.86 (+1.40%)
AMD   159.46 (+0.69%)
GE   96.50 (+1.59%)
MU   88.87 (+5.80%)
T   22.95 (+0.53%)
F   20.21 (+5.32%)
DIS   147.71 (+1.94%)
ACB   6.51 (+1.40%)
PFE   53.32 (-0.76%)
AMC   34.61 (+1.97%)
BA   200.22 (+1.20%)
S&P 500   4,635.25 (+1.49%)
DOW   34,878.33 (+1.14%)
QQQ   399.09 (+1.34%)
AAPL   167.92 (+1.58%)
MSFT   334.77 (+1.26%)
FB   327.84 (+1.04%)
GOOGL   2,901.36 (+2.23%)
AMZN   3,545.46 (+1.09%)
TSLA   1,164.34 (+1.71%)
NVDA   330.26 (+1.07%)
BABA   128.84 (+1.03%)
NIO   40.09 (+2.45%)
CGC   10.86 (+1.40%)
AMD   159.46 (+0.69%)
GE   96.50 (+1.59%)
MU   88.87 (+5.80%)
T   22.95 (+0.53%)
F   20.21 (+5.32%)
DIS   147.71 (+1.94%)
ACB   6.51 (+1.40%)
PFE   53.32 (-0.76%)
AMC   34.61 (+1.97%)
BA   200.22 (+1.20%)

ResMed Stock Forecast, Price & News

$253.38
-1.47 (-0.58%)
(As of 12/1/2021 10:14 AM ET)
Add
Compare
Today's Range
$252.66
$257.42
50-Day Range
$251.21
$288.48
52-Week Range
$179.37
$301.34
Volume
1,747 shs
Average Volume
590,664 shs
Market Capitalization
$36.92 billion
P/E Ratio
74.30
Dividend Yield
0.65%
Beta
0.3
30 days | 90 days | 365 days | Advanced Chart
Receive RMD News and Ratings via Email

Sign-up to receive the latest news and ratings for ResMed and its competitors with MarketBeat's FREE daily newsletter.


ResMed logo

About ResMed

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the following segments: Sleep and Respiratory Care, and Software as a Service. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment engages in the supply of business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Headlines

ResMed (NYSE:RMD) Shares Gap Up to $254.81
November 15, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
CUSIP
76115210
Employees
7,970
Year Founded
1989

Sales & Book Value

Annual Sales
$3.20 billion
Cash Flow
$6.68 per share
Book Value
$20.77 per share

Profitability

Net Income
$474.51 million
Pretax Margin
27.67%

Debt

Price-To-Earnings

Miscellaneous

Free Float
143,654,000
Market Cap
$36.92 billion
Optionable
Optionable

Company Calendar

Last Earnings
10/28/2021
Ex-Dividend
11/09/2021
Today
12/01/2021
Dividend Payable
12/16/2021
Next Earnings (Estimated)
1/27/2022
Fiscal Year End
6/30/2022

Social Links


MarketRank

Overall MarketRank

1.99 out of 5 stars

Medical Sector

635th out of 1,390 stocks

Surgical & Medical Instruments Industry

73rd out of 127 stocks

Analyst Opinion: 1.1Community Rank: 3.5Dividend Strength: 1.7Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -












ResMed (NYSE:RMD) Frequently Asked Questions

Is ResMed a buy right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last year. There are currently 2 sell ratings, 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ResMed stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RMD, but not buy additional shares or sell existing shares.
View analyst ratings for ResMed
or view top-rated stocks.

How has ResMed's stock price been impacted by COVID-19?

ResMed's stock was trading at $153.61 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, RMD shares have increased by 67.1% and is now trading at $256.73.
View which stocks have been most impacted by COVID-19
.

When is ResMed's next earnings date?

ResMed is scheduled to release its next quarterly earnings announcement on Thursday, January 27th 2022.
View our earnings forecast for ResMed
.

How were ResMed's earnings last quarter?

ResMed Inc. (NYSE:RMD) posted its quarterly earnings data on Thursday, October, 28th. The medical equipment provider reported $1.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.35 by $0.16. The medical equipment provider earned $904 million during the quarter, compared to analyst estimates of $858.20 million. ResMed had a net margin of 14.92% and a trailing twelve-month return on equity of 28.46%. ResMed's revenue for the quarter was up 20.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.27 earnings per share.
View ResMed's earnings history
.

How often does ResMed pay dividends? What is the dividend yield for ResMed?

ResMed announced a quarterly dividend on Thursday, October 28th. Investors of record on Thursday, November 11th will be given a dividend of $0.42 per share on Thursday, December 16th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 0.65%. The ex-dividend date is Tuesday, November 9th.
View ResMed's dividend history
.

Is ResMed a good dividend stock?

ResMed pays an annual dividend of $1.68 per share and currently has a dividend yield of 0.65%. ResMed does not yet have a strong track record of dividend growth. The dividend payout ratio of ResMed is 49.27%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, ResMed will have a dividend payout ratio of 24.71% next year. This indicates that ResMed will be able to sustain or increase its dividend.
View ResMed's dividend history.

What price target have analysts set for RMD?

10 brokerages have issued twelve-month price objectives for ResMed's shares. Their forecasts range from $221.00 to $270.00. On average, they anticipate ResMed's share price to reach $244.43 in the next year. This suggests that the stock has a possible downside of 4.8%.
View analysts' price targets for ResMed
or view top-rated stocks among Wall Street analysts.

Who are ResMed's key executives?

ResMed's management team includes the following people:
  • Mick Farrell, Chief Executive Officer & Director
  • Rob Douglas, President & Chief Operating Officer
  • Brett A. Sandercock, Chief Financial Officer
  • Carlos M. Nunez, Chief Medical Officer
  • Bobby Ghoshal, Chief Technology Officer & President-SaaS Business

What is Mick Farrell's approval rating as ResMed's CEO?

284 employees have rated ResMed CEO Mick Farrell on Glassdoor.com. Mick Farrell has an approval rating of 92% among ResMed's employees. This puts Mick Farrell in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ResMed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ResMed investors own include NVIDIA (NVDA), Walt Disney (DIS), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Adobe (ADBE), Visa (V), Alibaba Group (BABA), PayPal (PYPL) and QUALCOMM (QCOM).

What is ResMed's stock symbol?

ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."

Who are ResMed's major shareholders?

ResMed's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.71%), WCM Investment Management LLC (6.24%), Capital World Investors (2.52%), Geode Capital Management LLC (2.02%), Baillie Gifford & Co. (1.96%) and Invesco Ltd. (1.22%). Company insiders that own ResMed stock include Brett Sandercock, Carol Burt, Dave Michaud, David Pendarvis, James Hollingshead, Justin Leong, Michael J Farrell, Rajwant Sodhi, Robert Andrew Douglas and Ronald R Taylor.
View institutional ownership trends for ResMed
.

Which major investors are selling ResMed stock?

RMD stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Morgan Stanley, Victory Capital Management Inc., Eagle Asset Management Inc., Bank of New York Mellon Corp, Martingale Asset Management L P, Schroder Investment Management Group, and NFJ Investment Group LLC. Company insiders that have sold ResMed company stock in the last year include Brett Sandercock, Carol Burt, Dave Michaud, David Pendarvis, James Hollingshead, Rajwant Sodhi, Robert Andrew Douglas, and Ronald R Taylor.
View insider buying and selling activity for ResMed
or view top insider-selling stocks.

Which major investors are buying ResMed stock?

RMD stock was purchased by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, Arrowstreet Capital Limited Partnership, Geode Capital Management LLC, Goldman Sachs Group Inc., Martin Currie Ltd., Los Angeles Capital Management LLC, Barclays PLC, and Capstone Investment Advisors LLC.
View insider buying and selling activity for ResMed
or or view top insider-buying stocks.

How do I buy shares of ResMed?

Shares of RMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ResMed's stock price today?

One share of RMD stock can currently be purchased for approximately $256.73.

How much money does ResMed make?

ResMed has a market capitalization of $37.41 billion and generates $3.20 billion in revenue each year. The medical equipment provider earns $474.51 million in net income (profit) each year or $3.41 on an earnings per share basis.

How many employees does ResMed have?

ResMed employs 7,970 workers across the globe.

When was ResMed founded?

ResMed was founded in 1989.

What is ResMed's official website?

The official website for ResMed is www.resmed.com.

Where are ResMed's headquarters?

How can I contact ResMed?

ResMed's mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The medical equipment provider can be reached via phone at (858) 836-5000, via email at [email protected], or via fax at 858-836-5501.


This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.